Reshma Kewalramani - 27 Feb 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Reporting relationship: CEO & President, Director
Issuer ticker: VRTX
Reported as of: 27 Feb 2026
Net transaction value: -$19,738,855
SEC form: 4
Accepted by SEC: 03 Mar 2026, 16:34:23 UTC
Prior SEC filing: 26 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Christiana Stevenson, Attorney-in-Fact

Key filing fact

Reshma Kewalramani filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 03 Mar 2026.

Key facts

This page summarizes Reshma Kewalramani's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
13 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Mar 2026, 16:34.

Change

Previous filing in this sequence was filed on 26 Feb 2026.
Current net transaction value: -$19,738,855.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001735944 Primary reporting owner

Kewalramani Reshma

Relationship: CEO & President, Director
Address: C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON
Signature: /s/ Christiana Stevenson, Attorney-in-Fact
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRTX transaction

Common Stock

Sale

Transaction value: $191,900
Shares: -400
Change %: -0.29%
Price: $479.75
Shares after: 137,878
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F3

VRTX transaction

Common Stock

Sale

Transaction value: $57,780
Shares: -120
Change %: -0.09%
Price: $481.50
Shares after: 137,758
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F4

VRTX transaction

Common Stock

Sale

Transaction value: $115,882
Shares: -240
Change %: -0.17%
Price: $482.84
Shares after: 137,518
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F5

VRTX transaction

Common Stock

Sale

Transaction value: $1,222,696
Shares: -2,510
Change %: -1.8%
Price: $487.13
Shares after: 135,008
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F6

VRTX transaction

Common Stock

Sale

Transaction value: $1,600,549
Shares: -3,278
Change %: -2.4%
Price: $488.27
Shares after: 131,730
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F7

VRTX transaction

Common Stock

Sale

Transaction value: $225,087
Shares: -460
Change %: -0.35%
Price: $489.32
Shares after: 131,270
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F8

VRTX transaction

Common Stock

Sale

Transaction value: $1,336,722
Shares: -2,725
Change %: -2.1%
Price: $490.54
Shares after: 128,545
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F9

VRTX transaction

Common Stock

Sale

Transaction value: $466,244
Shares: -949
Change %: -0.74%
Price: $491.30
Shares after: 127,596
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F10

VRTX transaction

Common Stock

Sale

Transaction value: $1,243,091
Shares: -2,520
Change %: -2%
Price: $493.29
Shares after: 125,076
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F11

VRTX transaction

Common Stock

Sale

Transaction value: $1,729,166
Shares: -3,498
Change %: -2.8%
Price: $494.33
Shares after: 121,578
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F12

VRTX transaction

Common Stock

Sale

Transaction value: $7,718,020
Shares: -15,580
Change %: -13%
Price: $495.38
Shares after: 105,998
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F13

VRTX transaction

Common Stock

Sale

Transaction value: $2,974,479
Shares: -5,995
Change %: -5.7%
Price: $496.16
Shares after: 100,003
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F14

VRTX transaction

Common Stock

Sale

Transaction value: $857,239
Shares: -1,725
Change %: -1.7%
Price: $496.95
Shares after: 98,278
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F15

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 15 footnotes

Footnote F1

Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025.

Footnote F2

Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Footnote F3

Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76).

Footnote F4

Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51).

Footnote F5

Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85).

Footnote F6

Open market sales reported on this line occurred at a weighted average price of $487.13 (range $486.64 to $487.55).

Footnote F7

Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56).

Footnote F8

Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79).

Footnote F9

Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01).

Footnote F10

Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85).

Footnote F11

Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77).

Footnote F12

Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75).

Footnote F13

Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78).

Footnote F14

Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74).

Footnote F15

Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17).